Rosen Quoted on FDA Warning Letters Issued to Drug Compounders
31 January 2014
Inside Health Policy
Partner David Rosen was quoted in an Inside Health Policy article on January 31, 2014 titled, “First DQSA Warning Letters Target Compounders Without Prescriptions.” The article discusses the two warning letters issued by the FDA to drug compounders in recent weeks chastising them for lacking patient-specific prescriptions. Rosen was quoted saying, “If you do not have an individual prescription for every patient for whom you compound, this is one way FDA is sending the message that you are not compliant with 503A at this time.”
People
Related News
08 November 2024
In the News
Federico Goudie on Brazil as Key Market – 'It just happens that Miami is a smart place to be'
Foley & Lardner LLP partner Federico Goudie shared insight on the growing importance of Brazil to the U.S. legal market in Daily Business Review, identifying Miami as a key place to be for firms working with Brazilian clients and Latin American clients more broadly.
08 November 2024
In the News
Louis Lehot Assesses 2024 Election Result, Prospect of Tech Deal Resurgence
Foley & Lardner LLP partner Louis Lehot appeared across legal and business press to discuss the likelihood of a resurgence across capital markets, venture capital, and tech M&A following the results of the 2024 U.S. presidential election.
07 November 2024
In the News
James McKee on Amendment 3's Failed Passage – 'Florida still has a significant market'
Foley & Lardner LLP partner James McKee's assessment of the future of the cannabis industry in Florida following the failed passage of Amendment 3, a constitutional amendment that would have legalized recreational use of marijuana for adults, appeared across media outlets, including CBS News Miami, NBC 6 South Florida, NPR/WUSF, Orlando Sentinel, South Florida Sun Sentinel, and WMNF 88.5 FM.